GILD Gilead Sciences, Inc.
Healthcare$133.73-0.47%ClosedMarket Cap: $166.04B
As of 2026-05-26
Valuation
P/E (TTM)
20.28
PEG
0.01
P/B
7.10
P/S
5.61
EV/EBITDA
13.61
DCF Value
$172.53
FCF Yield
6.1%
Div Yield
2.4%
Margins & Returns
Gross Margin
79.4%
Operating Margin
38.3%
Net Margin
31.0%
ROE
42.2%
ROA
16.4%
ROIC
20.3%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $6.96B | 79.2% | $2.59B | $2.02B | $— | $0.82 |
| Q4 null | $7.92B | 79.5% | $2.99B | $2.18B | $— | $0.79 |
| FY null | $29.44B | 78.8% | $11.70B | $8.51B | $— | $3.16 |
| Q3 null | $7.77B | 79.8% | $3.33B | $3.05B | $— | $0.79 |
| Q2 null | $7.08B | 78.8% | $2.47B | $1.96B | $— | $0.79 |
| Q1 null | $6.67B | 76.9% | $2.24B | $1.31B | $— | $0.79 |
| Q4 null | $7.57B | 79.1% | $2.45B | $1.78B | $— | $0.77 |
| FY null | $28.75B | 78.3% | $1.66B | $480.0M | $— | $3.08 |
| Q3 null | $7.54B | 79.1% | $888.0M | $1.25B | $— | $0.77 |
| Q2 null | $6.95B | 77.8% | $2.64B | $1.61B | $— | $0.77 |
| Q1 null | $6.69B | 76.8% | $-4.32B | $-4.17B | $— | $0.77 |
| Q4 2023 | $7.11B | 70.6% | $1.61B | $1.43B | $1.14 | $0.75 |